Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (project Metarthros)
Deutsche Forschungsgemeinschaft (CRC1181 (project INST 90/925-1), FOR 2886 (project SCHE 1583/15-1), project SCHE 1583/14-1)
Innovative Medicines Initiative (RTCure (115142))
Foundation for Research in Rheumatology
Received: 6 March 2019
Accepted: 8 July 2019
First Online: 26 July 2019
Ethics approval and consent to participate
: IVEPSA was part of the PSARTROS study program (NCT02483234) with two separate studies, one on PsA and one patient at high risk to develop PsA. All patients provided written informed consent, and institutional review board (IRB)/ethics committee (Ethik-Kommission der Friedrich-Alexander-Universität Erlangen-Nürnberg) approved the protocol (EC 63_15Az; IRB 2355/01).
: Not applicable
: The authors declare that they have no competing interests.